Regulatory landscape

Not approved anywhere, and recently restricted

Ipamorelin is not approved as a medicine by any regulator in the world. Both companies that developed it walked away, and in the United States it was specifically restricted from compounding after a 2024 advisory-committee vote. Understanding this status is essential to reading any claim about it honestly.

This unit covers why the original sponsors discontinued it, the 2023-2024 FDA compounding saga, its anti-doping status under WADA, and how to interpret the research-chemical labeling that lets it still be sold. The legal reality is as much a part of the honest picture as the pharmacology.